LON:AREC Arecor Therapeutics (AREC) Share Price, News & Analysis GBX 72 +1.50 (+2.13%) As of 09/5/2025 08:23 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Arecor Therapeutics Stock (LON:AREC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Arecor Therapeutics alerts:Sign Up Key Stats Today's Range 70.50▼ 7250-Day Range 42.30▼ 7252-Week Range 35.40▼ 82Volume26,727 shsAverage Volume36,134 shsMarket Capitalization£27.19 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. For further details please see our website, www.arecor.com Read More Receive AREC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arecor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AREC Stock News HeadlinesTRADING UPDATES: Gem Resources raises funds; Afentra Angolan progressSeptember 4, 2025 | lse.co.ukArecor Therapeutics Secures FDA Approval for Innovative Insulin Study DesignSeptember 4, 2025 | msn.comStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today. | Paradigm Press (Ad)LON:AREC Financials | Arecor Therapeutics PLC - Investing.comAugust 23, 2025 | investing.comArecor Therapeutics And 2 Other UK Penny Stocks To ConsiderJuly 31, 2025 | finance.yahoo.comSkye and Arecor to develop higher formulation of CB1 inhibitorMay 20, 2025 | finance.yahoo.comArecor Chair Increases Stake with Share PurchaseMay 14, 2025 | tipranks.comSMALL-CAP MOVERS: Is popping AIM ready to really blow up? One research house reckons soMay 10, 2025 | uk.investing.comSee More Headlines AREC Stock Analysis - Frequently Asked Questions How have AREC shares performed this year? Arecor Therapeutics' stock was trading at GBX 73.75 at the beginning of 2025. Since then, AREC stock has decreased by 2.4% and is now trading at GBX 72. How were Arecor Therapeutics' earnings last quarter? Arecor Therapeutics plc (LON:AREC) posted its quarterly earnings data on Tuesday, April, 22nd. The company reported ($0.31) earnings per share (EPS) for the quarter. Arecor Therapeutics had a negative net margin of 176.89% and a negative trailing twelve-month return on equity of 118.67%. How do I buy shares of Arecor Therapeutics? Shares of AREC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Arecor Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arecor Therapeutics investors own include Pfizer (PFE), NVIDIA (NVDA), PayPal (PYPL), Advanced Micro Devices (AMD), Cisco Systems (CSCO), Lowe's Companies (LOW) and SNDL (SNDL). Company Calendar Last Earnings4/22/2025Today9/07/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryCoal Current SymbolLON:AREC CIKN/A Webwww.americanresourcescorp.com Phone44 1223 426 060FaxN/AEmployees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£10.68 million Net Margins-176.89% Pretax MarginN/A Return on Equity-118.67% Return on Assets-37.31% Debt Debt-to-Equity Ratio5.51 Current Ratio1.37 Quick Ratio6.24 Sales & Book Value Annual Sales£5.05 million Price / Sales5.38 Cash FlowGBX 14.20 per share Price / Cash Flow5.07 Book ValueGBX 16.58 per share Price / Book4.34Miscellaneous Outstanding Shares37,757,000Free FloatN/AMarket Cap£27.19 million OptionableNot Optionable Beta-0.18 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (LON:AREC) was last updated on 9/8/2025 by MarketBeat.com Staff From Our PartnersThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored6-Figure Target for BTC by 2025Trump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arecor Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Arecor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.